Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

PVCT $1.00 0.1399 +16.27%
ONCY $0.82 0.1020 +14.21%
BIND $8.94 1.1100 +14.18%
INCY $64.18 6.3100 +10.90%
XLRN $38.24 3.5000 +10.07%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CNDO $1.70 -0.1000 -5.56%
AEZS $1.06 -0.0500 -4.50%
ARGS $9.66 -0.3600 -3.59%
APRI $1.58 -0.0500 -3.07%
CRIS $1.27 -0.0400 -3.05%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | Next > | Last >>

DNA Said to Protect Hispanic Women From Breast Cancer

(Wall Street Journal) Oct 20, 2014 - A genetic trait protects many women of Latin American descent from breast cancer, researchers probing the ethnic biology of cancer said Monday.
read article (paid subscription required) 

Genetic Variant Protects Some Latina Women from Breast Cancer

(UCSF News) Oct 20, 2014 - An international research collaboration led by UC San Francisco researchers has identified a genetic variant common in Latina women that protects against breast cancer.
read article 

Urge Your Representative to Support SGR Repeal

(ASCO in Action) Oct 17, 2014 - Representatives Reid Ribble (R-WI) and Kurt Schrader (D-OR) are asking fellow Representatives to sign a letter to leadership of the House of Representatives asking them to take action this year to eliminate the flawed sustainable growth rate (SGR) formula used to set Medicare physician payments and enact fiscally responsible reforms to the system.
read article 

CMS to Reopen Meaningful Use Hardship Exemption; Deadline to Attest Extended to Nov. 30

(ASCO in Action) Oct 17, 2014 - The Centers for Medicare & Medicaid Services (CMS) this week announced the reopening of its Meaningful Use (MU) hardship exception application for physicians and hospitals to avoid the 2015 penalty.
read article 

FDA Panel: Chantix Boxed Warning Should Stay

(MedPage Today) Oct 16, 2014 - An FDA advisory committee voted overwhelmingly that the stop-smoking drug should continue to carry a boxed warning about the risk of severe neuropsychiatric events, with several panel members suggesting it should be strengthened.
read article (free registration required) 

Chimerix Gets FDA OK to Test Drug For Ebola

(ABC News/Associated Press) Oct 17, 2014 - A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.
read article 

Amgen Files Patent Infringement Suit Over Cholesterol Drug

(Wall Street Journal) Oct 17, 2014 - Amgen Inc. said Friday that it has filed a patent-infringement lawsuit against Regeneron Pharmaceuticals Inc. and Sanofi SA over their experimental cholesterol drug, alirocumab.
read article (paid subscription required) 

Regeneron's Eylea Works Better vs Avastin and Lucentis in Study

(Reuters) Oct 17, 2014 - Regeneron Pharmaceuticals Inc said on Friday that a head-to-head study showed that its Eylea treatment for diabetic macular edema created significantly greater improvement in visual acuity compared with Genentech's Avastin and Lucentis.
read article 

Collapse of AbbVie-Shire Deal Leaves Scars

(Wall Street Journal) Oct 16, 2014 - The likely collapse of AbbVie Inc.’s $54 billion agreement to buy Shire PLC leaves two global drug companies in need of new, independent courses and investors and Wall Street bankers smarting from losses and fees they won’t collect.
read article (paid subscription required) 

Ron Klain, Chief of Staff to 2 Vice Presidents, Is Named Ebola Czar

(New York Times) Oct 17, 2014 - President Obama will appoint Ron Klain, a former chief of staff for Vice Presidents Al Gore and Joseph R. Biden Jr., to manage the government’s response to the deadly virus as anxiety grows over its possible spread, a White House official said on Friday.
read article 

EKF Molecular and Massachusetts General Hospital Announce Circulating Tumour Cell Clinical Research Collaboration

(Lab Bulletin) Oct 17, 2014 - EKF Diagnostics, the global diagnostics company, announces that it has entered into a two year research collaboration with Massachusetts General Hospital (MGH), a global leader in successfully bridging innovative science with state-of-the-art clinical medicine, to develop PointMan™ assays that can effectively detect treatable cancer mutations in blood samples.
read article 

Batu Biologics Awarded Exclusive License From University of California San Diego For Drug That Stimulates Immune System to Kill Cancer

(Yahoo! Finance) Oct 16, 2014 - Batu Biologics announced today the signing of a license agreement with the Regents of the University of California, granting exclusive rights to novel peptide drugs developed at UC San Diego that have been proven to stimulate cancer-killing immune responses.
read article 

Centers for Medicare and Medicaid Services Publishes Draft Coverage Decision to Reimburse the Decipher® Test For Intermediate & High Risk Prostate Cancer

(Yahoo! Finance) Oct 16, 2014 - GenomeDx Biosciences today announced that a draft local coverage determination (LCD) for its Decipher® Prostate Cancer Classifier has been published by the Centers for Medicare and Medicaid Services (CMS) describing a coverage and payment policy for use of the Decipher test in men who have undergone radical prostatectomy.
read article 

Myriad Receives Draft Medicare Coverage For Prolaris

(CNNMoney) Oct 17, 2014 - Myriad Genetics, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for Prolaris, Myriad's revolutionary prostate cancer test.
read article 

Bladder Cancer Drug Shortages and Price Gouging: The New Reality

(Forbes) Oct 16, 2014 - Clearly the market for bladder cancer therapeutics is suffering a crisis of consistency and reliability. The new FDA legislation initially touted as preventing this problem has had no effect.
read article 

Two Tracks, One Destination: Quality Care

(ACCCBuzz) Oct 13, 2014 - Last week hundreds of cancer care providers gathered in San Diego for the 31st ACCC National Oncology Conference. Over two days, attendees joined in a range of dynamic sessions focused around two track themes: YOUR PATIENTS and YOUR PROGRAM.
read article 

Solution to US Cancer Care 'Crisis' Is Less Cancer Care

(Medscape Medical News) Oct 16, 2014 - There is a need to revise the disease-centric approach that requires that all cancers be treated, regardless of age, comorbidities, and likely side effects. Overall well-being should be paramount, say a pair of reformers.
read article (free registration required) 

CAR T-Cells in Leukemia: Expert Commentary

(Medscape Medical News) Oct 16, 2014 - We catch up with Catherine Bollard, MD, from the Children's National Medical Center in Washington, DC, who will be presenting an educational session about CAR T-cell therapy at the American Society of Hematology (ASH) annual meeting in December 2014.
read article (free registration required) 

Pharmacyclics Enters Into Agreement With Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and Leukemia

(Yahoo! Finance) Oct 16, 2014 - Pharmacyclics, Inc. today announced that it has entered into a master clinical drug supply agreement with Roche to evaluate the safety, tolerability and preliminary efficacy of IMBRUVICA® (ibrutinib) in combination with GAZYVA® (obinutuzumab).
read article 

Adaptimmune Announces Interim Results From Pilot Trial of its Engineered NY-ESO T Cells Targeting Synovial Sarcoma

(Adaptimmune) Oct 17, 2014 - Adaptimmune Limited today announces the release of interim results from a pilot clinical trial 04511 of NY-ESOc259T which uses a patient’s own T cells that have been genetically altered to attack synovial sarcoma cells.
read corporate press release 

CytRx to Present Data From Global Phase 2b Clinical Trial of Aldoxorubicin in First-Line Soft Tissue Sarcoma at 2014 CTOS Annual Meeting

(CNBC) Oct 17, 2014 - Due to the longer than expected survival of patients in the clinical trial, there have not been a sufficient number of survival events to enable the Company to report data on overall survival, a secondary endpoint of the study.
read article 

Pitt/McGowan Institute Team Discovers Stem Cells in the Esophagus

(UPMC) Oct 16, 2014 - Despite previous indications to the contrary, the esophagus does have its own pool of stem cells, said researchers from the University of Pittsburgh School of Medicine in an animal study published online today in Cell Reports.
read press release 

Human Cancer Prognosis Is Related to Newly Identified Immune Cell

(UCSF) Oct 16, 2014 - A newly discovered population of immune cells in tumors is associated with less severe cancer outcomes in humans, and may have therapeutic potential, according to a new UC San Francisco study of 3,600 human tumors of 12 types, as well as mouse experiments.
read article 

Exercise Cuts Later CV Risk in Hodgkin’s Lymphoma Survivors

(Doctors Lounge/HealthDay News) Oct 16, 2014 - Exercise may lower the risk of treatment-related cardiovascular events in adult survivors of childhood Hodgkin's lymphoma, according to research published online Oct. 13 in the Journal of Clinical Oncology.
read article 

Diet May Influence Ovarian Cancer Survival

(Reuters Health) Oct 16, 2014 - Women with healthier diets before an ovarian cancer diagnosis are less likely to die in the years following the cancer than women with poorer diets, according to a new study.
read article